About Us

QuintilesIMS delivers integrated information and technology solutions to drive healthcare forward

Around the world healthcare stakeholders are working to improve real-world patient outcomes through treatment innovations, care provision and access to healthcare. For the information, technology and service solutions they need to drive new insights and approaches, they count on QuintilesIMS. With a global team of 50,000, we harness insights, commercial and scientific depth, and executional expertise to empower clients to achieve some of their most important goals: Improving clinical, scientific and commercial results. Realizing the full potential of innovations. And, ultimately, driving healthcare forward.

Our Joint History

 

October 3, 2016

QuintilesIMS starts a new chapter as a publicly traded company (NYSE:Q). The company’s 50,000 professionals serve clients in 100+ markets—working to advance healthcare by seamlessly connecting clinical and commercial execution to real-world outcomes.

May 3, 2016

IMS and Quintiles announce intention to merge to create a global leader in healthcare intelligence.

2015

IMS acquires Cegedim’s CRM business and strategic data assets—affirming its position as the first global enterprise focused on connecting solutions across information, technology and services to drive healthcare performance.

2014

IMS goes public again following four years as a private company.

2013

IMS completes a series of strategic acquisitions to strengthen technology services and solutions—including social media listening, multichannel marketing and performance management, as well as technology-enabled Real-World Insights solutions.

2011

Quintiles acquires Outcome Sciences, positioning Quintiles as the industry powerhouse in late-phase and real-world research.

2011

IMS expands specialty and anonymized patient-level data assets in the U.S. with the acquisition of SDI Health.

2010

IMS is taken private by TPG Capital, CPP Investment Board and Leonard Green & Partners. Valued at close to $6 billion, the deal is the largest leveraged buyout transaction closed in the prior three years.

2003

Quintiles becomes a private company led by founder and Chairman Dennis Gillings, CBE, PhD.

2002

IMS extends consulting and advisory services by acquiring U.K.-based Cambridge Pharma Consultancy.

1998

IMS becomes an independent, NYSE-listed public company.

1996

Quintiles combines with Innovex Ltd., a UK-based contract pharmaceutical company specializing in sales and marketing services for pharmaceutical clients, creating the world’s largest full-service biopharmaceutical services company.

1996

Quintiles establishes its Consulting practice with the acquisition of a globally recognized healthcare policy research and management consulting company.

1994

Quintiles goes public, completing an initial public offering of Quintiles stock.

1992

Quintiles Laboratories Ltd. opens in Atlanta, expanding from one small room offering safety testing to a global network with a full-service offering, before becoming Q2LabSolutions in a transaction with Quest Diagnostics.

1988

D&B acquires IMS for nearly $1.7 billion to leverage the complementary strengths of IMS and sister division A.C. Nielsen.

1982

Dennis Gillings and Gary Koch, professors at the University of North Carolina, co-found Quintiles with a team of part-time staff working in a trailer on the UNC campus where they provide statistical and data management consulting for pharmaceutical clients.

1979

IMS launches MIDAS, which gives clients access to IMS databases from terminals in their offices.

1973

IMS acquires Cambridge Computer, the creator of Drug Distribution Data (DDD), which becomes one of IMS's most significant product lines.

1957

IMS publishes its first European syndicated research study: an audit of pharma sales in West Germany. Acquisitions in South Africa, Australia and New Zealand follow.

1954

Bill Frohlich, an ad executive, and David Dubow, a visionary, form IMS as the first independent, objective source of information about the pharmaceutical industry.